Publications

Research outputs, reports, policy briefs and knowledge products from KIU scholars and partners.

2024 School of Allied Health Sciences IDOSR JOURNAL OF APPLIED SCIENCES

Prevalence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) in Nigeria

Samson Ohwonohwo Onemu1, Emmanuel Ifeanyi Obeagu2, Famutimi Yetunde Bodunde1, Abdulrahman Abdulbasit Opeyemi1, Olamijuwon Priscilla Busola1, Ayara Peter Ayowole1 and Abdulwasiu Oladele Hassan1.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains one of the most challengingpandemics in the world with fewer casualties in Nigeria despite minimal vaccine uptake. This study examinesthe prevalence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) in subjects attending FederalMedical Center, Owo, Ondo State. A questionnaire based descriptive cross-sectional was conducted in 2022among 100 patients from Federal Medical Centre in Owo, Ondo State .50 of whom had received the COIVD-19vaccine and 50 of whom had not. For this study, men and women between the ages of 18 and 55 who appearedto be in good health were included. According to the study's findings, the prevalence of SARS-CoV-2 wasdetected in 5% of the population while it was absent in 95% of the rest. Two (2.00%) men and three (3.00%)women out of the five who confirmed positive for SARS CoV 2. The findings also revealed that, of the 5participants who were tested positive for SARS CoV 2, 4 (80.00%) had not had a vaccination, while 1 (20.00%)had. Adult Nigerians who have never received the COVID-19 vaccine have a high SARS-CoV-2 antibody seroprevalencerate. Age and gender do not appear to significantly correlate with sero-positivity (p>0.05). Therefore,anti-SARS-CoV-2 antibody testing is required after vaccination since it may be necessary to achieve herdimmunity.Keywords: antibody; SARS-CoV-2; Sero-prevalence; vaccine; Covid-19